AstraZeneca plc (LON:AZN) Plans Dividend of GBX 146.40
AstraZeneca plc (LON:AZN) declared a dividend on Friday, February 14th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, February 27th will be paid a dividend of GBX 146.40 ($1.93) per share by the biopharmaceutical company on Monday, March 30th. This represents a yield of 1.92%. The ex-dividend date of this dividend is Thursday, February 27th. This is a positive change from AstraZeneca’s previous dividend of $71.90. The official announcement can be accessed at this link.
LON:AZN traded down GBX 288 ($3.79) during trading hours on Friday, hitting GBX 7,338 ($96.53). 2,048,936 shares of the stock traded hands, compared to its average volume of 2,310,000. The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 148.59. AstraZeneca has a 1 year low of GBX 109.51 ($1.44) and a 1 year high of GBX 8,227.88 ($108.23). The company has a market cap of $100.07 billion and a price-to-earnings ratio of 46.04. The stock has a 50 day moving average price of GBX 7,668.20 and a 200 day moving average price of GBX 7,328.85.
Several brokerages have weighed in on AZN. UBS Group reaffirmed a “sell” rating and set a GBX 5,800 ($76.30) price target on shares of AstraZeneca in a report on Monday, February 3rd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Friday. Liberum Capital reissued a “buy” rating on shares of AstraZeneca in a report on Friday. Deutsche Bank reissued a “buy” rating and issued a GBX 8,400 ($110.50) target price on shares of AstraZeneca in a report on Tuesday, January 28th. Finally, Bryan, Garnier & Co reissued a “buy” rating on shares of AstraZeneca in a report on Thursday, December 19th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of GBX 7,912.14 ($104.08).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: P/E Growth (PEG)
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.